IBRX261030C00008000
IBRX Oct 30 2026 8.00 Call
optionOPRA
EODOct 16, 2026
1.42USD-29.000%(-0.58)8Vol45OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
8
Expiration
Oct 30, 2026
DTE
10d
Moneyness
ITM
Intrinsic
$0.48
IBRX 8 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.17 | +3.33% | 11 | 23 |
| Oct 30, 2026 | 10d | $1.42 | -29.00% | 8 | 45 |
| Nov 6, 2026 | 17d | $1.85 | -31.23% | 10 | 507 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $1.75 | -28.57% | 129 | 1,315 |
| Nov 27, 2026 | 38d | $1.90 | -25.49% | 2 | 11 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $3.00 | -11.76% | 59 | 1,300 |
| Apr 16, 2027 | 178d | $4.16 | +69.80% | 20 | 96 |
| May 21, 2027 | 213d | $3.00 | +13.21% | 2 | 3 |
IBRX Nearby Strikes · Oct 30, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5 C | $5.80 | +62.01% | 1 | 1 | ITM |
| 5.5 C | $3.03 | -9.01% | 1 | 1 | ITM |
| 6 C | — | — | 0 | 0 | ITM |
| 6.5 C | — | — | 0 | 0 | ITM |
| 7 C | $3.76 | +34.29% | 7 | 7 | ITM |
| 7.5 C | $2.75 | -17.91% | 4 | 94 | ITM |
| 8 C | $1.42 | -29.00% | 8 | 45 | ITM |
| 8.5 C | $1.48 | +11.28% | 7 | 20 | OTM |
| 9 C | $0.74 | -50.67% | 437 | 1,164 | OTM |
| 9.5 C | $1.24 | +1.64% | 8 | 114 | OTM |
| 10 C | $0.32 | -54.29% | 35 | 768 | OTM |
| 10.5 C | $0.22 | -60.00% | 64 | 468 | OTM |
| 11 C | $0.25 | -28.57% | 23 | 2,025 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.